Latest news from this key annual diabetes conference covering the latest in medtech, treatments, research and 'cures'.
The Advanced Technologies & Treatments for Diabetes (ATTD) conference is held annually and although aimed at those involved in the medtech sector and healthcare professionals, it often showcases new product innovations and gives insights into diabetes management that directly affects those managing the condition.
Here, we give a summary of some of the news coming out of the event.
Dexcom releases data on new 15-Day CGM
Dexcom has released the first data on its new 15-day CGM ahead of a presentation at ATTD. The new device would position Dexcom to compete directly with the Freestyle Libre 3 Plus sensor, which also offers a 15-day wear period.
Dexcom's Chief Operating Officer Jake Leach stated that the company aims to secure FDA clearance for the new sensor in the second half of the year.
The new CGM demonstrates a mean absolute relative difference (MARD) of 8%, which would make it the most accurate CGM available.
| Note, MARD measures the average difference between the device’s readings and reference measurements, such as fingerprick tests, with a lower value indicating greater accuracy. |
Tandem announces pivotal trial results for Type 2
Tandem Diabetes Care has released new clinical trial data supporting the FDA clearance of its Control-IQ+ algorithm for individuals with Type 2 diabetes. This milestone makes Tandem the second company to receive authorisation for an automated insulin delivery system that integrates glucose monitor data with insulin pumps, following Insulet’s expanded indication approval in August.
The randomised controlled trial enrolled 319 participants, comparing outcomes for those using the Control-IQ+ algorithm paired with Dexcom’s G6 sensor against a control group using their usual insulin delivery method. The study found that Control-IQ+ users experienced a 0.9% reduction in A1C levels, compared to a 0.3% reduction in the control group.
Additionally, time spent within the target blood sugar range improved significantly among Control-IQ+ users, increasing by 16%—equivalent to an additional 3.4 hours per day—compared to the control group.
These results mark an important step in expanding access to automated insulin delivery solutions for individuals with Type 2 diabetes. However, analysts suggest that Omnipod is likely to retain its majority market share as the choice for AID due to its patch pump design.
The findings have been published in the New England Journal of Medicine.
Insulet highlights Type 2 analysis in Automated Insulin Delivery trial
Insulet has released details from a trial supporting its Type 2 diabetes indication for its automated insulin delivery (AID) system. The study found that patients with Type 2 diabetes who use insulin experienced similar glycemic improvements—such as reductions in HbA1c and increased time in range—regardless of whether they were also taking GLP-1 or SGLT2 medications.
As medications like Ozempic and Mounjaro gain widespread use, diabetes technology companies are working to show that CGMs and insulin pumps remain valuable tools for patients, even those on newer drug therapies.
With diabetes management evolving rapidly, these findings reinforce the role of AID systems in providing effective glucose control for a broad range of users.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.